Ombea - Yes / No?

Question 1

Branded PV/MF

Answer 1

Yes

Question 2

Treatment Considerations in Polycythemia Vera and Myelofibrosis: A Real-World Patient Case Discussion

Answer 2

Yes

Question 3

Branded PV

Answer 3

Yes

Question 4

Intervening with Jakafi® (ruxolitinib) to Achieve Durable Count Control: Real-World Patient Case Discussion

Answer 4

Yes

Question 5

Branded MF

Answer 5

Yes

Question 6

Intervening With Jakafi® (ruxolitinib) at Diagnosis in Patients With Intermediate- or High-Risk Myelofibrosis | A Real World Patient Case Discussion

Answer 6

Yes

Question 7

GVHD

Answer 7

No

Question 8

Consider Jakafi ® (ruxolitinib) At the First Sign of Steroid-Refractory Acute GVHD

Answer 8

No

Question 9

PEMAZYRE

Answer 9

No

Question 10

The First and Only Treatment for Locally Advanced or Metastatic Cholangiocarcinoma

Answer 10

No

Question 11

MONJUVI

Answer 11

No

Question 12

Monjuvi (tafasitamab-cxix) for Use as Second-Line Therapy in Adult Patients with R/R DLBCL, in Combination with Lenalidomide

Answer 12

No

Question 13

Virtual Abridged Branded PV

Answer 13

No - Zoom Polling

Question 14

Intervening With Jakafi® (ruxolitinib) to Achieve Durable Count Control—Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea

Answer 14

No - Zoom Polling

Question 15

Virtual Abridged Branded MF

Answer 15

No - Zoom Polling

Question 16

Intervening With Jakafi® (ruxolitinib) at Diagnosis in Patients With Intermediate- or High-Risk Myelofibrosis

Answer 16

No - Zoom Polling

Question 17

Virtual Abridged GVHD

Answer 17

No

Question 18

Consider Jakafi ® (ruxolitinib) At the First Sign of Steroid-Refractory Acute GVHD

Answer 18

No

Question 19

Inst. Branded MF

Answer 19

Yes

Question 20

Intervening With Ruxolitinib at Diagnosis in Patients With Intermediate- or High-Risk Myelofibrosis - Real-World Patient Case Discussion

Answer 20

Yes

Question 21

Inst. Branded PV

Answer 21

Yes

Question 22

Intervening With Ruxolitinib to Achieve Durable Count Control: Real-World Patient Case Discussion - Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea

Answer 22

Yes

Question 23

Journal Article Review: COMFORT 5 year

Answer 23

No

Question 24

AN IN-DEPTH REVIEW:

Long-Term Findings From COMFORT-II, a Phase 3 Study of Ruxolitinib vs Best Available Therapy for Myelofibrosis

Answer 24

No

Question 25

Journal Article Review: Response 1

Answer 25

No

Question 26

AN IN-DEPTH REVIEW:

Ruxolitinib Versus Standard Therapy for the Treatment of Polycythemia Vera

Answer 26

No

Question 27

Journal Article Review: Response 2

Answer 27

No

Question 28

AN IN-DEPTH REVIEW:
Ruxolitinib for the treatment of
inadequately controlled polycythemia
vera without splenomegaly

Answer 28

No

Question 29

Journal Article Review: REACH2

Answer 29

No

Question 30

Consider Jakafi® (ruxolitinib)
At the First Sign of Steroid-Refractory
Acute GVHD
In adult and pediatric patients 12 years and older

Answer 30

No

Question 31

Journal Article Review: RESPONSE 5

Answer 31

No

Question 32

AN IN-DEPTH REVIEW:
Long-Term Efficacy and Safety of
Ruxolitinib Versus Best Available Therapy
in Polycythaemia Vera (RESPONSE):
5-Year Follow Up of a Phase 3 Study

Answer 32

No

Question 33

Inst. Unbranded PV

Answer 33

Yes

Question 34

Identifying Patients With Clinical Characteristics of Advanced Polycythemia Vera— Real-World Patient Case Discussion

Answer 34

Yes

Question 35

Unbranded PV

Answer 35

Yes

Question 36

Identifying Patients With Clinical Characteristics of Advanced Polycythemia Vera— Real-World Patient Case Discussion

Answer 36

Yes

Question 37

Virtual Abridged Unbranded PV

Answer 37

No – Zoom Polling

Question 38

Identifying the Clinical Characteristics of Advanced Polycythemia Vera

Answer 38

No – Zoom Polling